Real world outcome analysis of the two McGill University–associated hospitals with Lu-177 PRRT for metastatic NET.

• DOI: 10.1200/jco.2025.43.16_suppl.e16347
• Publication Date: 2025-05-28T15:26:18Z
• Authors: Uri Bender; Victoria Mandilaras; Petr Kavan; Hanan Zahed; Gad Abikhzer; Shawn Karls

e16347

Background: Neuroendocrine tumours (NET) are a heterogenous group of neoplasms that arise from neuroendocrine cells within various organs. Their aggressivity and metastatic potential varies vastly based on the anatomic site of origin and the histopathological grade. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) are the most common NETs accounting for 55-70% of all diagnosed NETs. Despite the benefits in PFS, response rates and likely OS as a result of the use of Lutathera, its implementation in wider clinical practice outside the established PRRT centres in Europe and the US has been rather slow due to difficulties with acquisition of Dotatate imaging and subsequent treatment, as only certain specialized centres have experience and access to the required resources. At McGill, both the MUHC and the Jewish General Hospital offer PRRT for GEP-NETs. The aim of this retrospective cohort study is to investigate local institutional practices in relation to 177-Lu DOTATATE PRRT in GEP-NETs. Real world data from the MUHC and the JGH will be analyzed in order determine treatment responses and associated sequencing of treatment. Methods: This retrospective cohort study aims to assess response rates in all patients treated with PRRT at the MUHC and the Jewish General Hospital since the initiation of the 177-Lu DOTATATE treatment program. The data was obtained through retrospective chart review and includes a cohort comprised of patients from both the Jewish General Hospital and the MUHC. Baseline demographics, as well as treatment-related demographics were obtained. Descriptive statistics were be calculated for the overall population using frequencies for categorical variables and means (SDs) or medians (interquartile ranges) for continuous and count variables. Survival/progression free survival estimates were computed using the Kaplan-Meier method. Potential association between variables was measured using Pearson correlation coefficients, chi-square tests, one- or two-sample t-tests.